Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/ciaa1673
- PMID
- 33146720
- PMCID
- PMC8664440
- OpenAlex
- W3096456697
- Study type
- Randomised controlled trial
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
The paper is relevant to influenza vaccine development, especially efforts to improve breadth of immune responses against homologous and drifted strains in older adults. It may be useful for literature review on vaccine immunogenicity and tolerability, but it does not establish real-world effectiveness.
Structured evidence summary
Research question
The study asked whether a Matrix-M-adjuvanted recombinant hemagglutinin quadrivalent nanoparticle influenza vaccine was safe and immunogenic in healthy adults aged 65 years or older.
Study design
This was a randomized, observer-blind, comparator-controlled trial comparing qNIV with trivalent high-dose inactivated influenza vaccine and quadrivalent recombinant influenza vaccine. The trial assessed safety and immunogenicity.
Population and setting
Healthy adults aged 65 years or older were enrolled. A total of 1,375 participants were randomized, vaccinated, and followed in the trial.
Main findings
The adjuvanted qNIV produced stronger wild-type hemagglutination-inhibition responses than unadjuvanted qNIV for 5 of 6 homologous or drifted strains. The 75 µg Matrix-M formulation also showed higher responses than IIV3-HD for several A/H3N2 strains, similar responses to IIV3-HD for A/H1N1 and B Victoria strains, and similar responses to RIV4 across the strains tested; it also generated larger influenza HA-specific polyfunctional CD4+ T-cell fold increases than either comparator. Reported adverse event frequencies were similar across groups.
Public-health relevance
The paper is relevant to influenza vaccine development, especially efforts to improve breadth of immune responses against homologous and drifted strains in older adults. It may be useful for literature review on vaccine immunogenicity and tolerability, but it does not establish real-world effectiveness.
Important limitations
The summary is limited to the supplied single-article abstract and metadata, so details from the full paper are unavailable for decision-grade interpretation. The abstract reports immunogenicity and safety findings, not clinical protection outcomes.
GIDS interpretation
This article is discoverable as a peer-reviewed randomized influenza vaccine trial in older adults and is contextually relevant to vaccine literature indexing. It should be treated as a study of immunogenicity and tolerability rather than as evidence of a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.